Medical Device Network on MSN5d
Novo Holdings and TA Associates back BiocompositesNovo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...
Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.
Life sciences tools company Esco Lifesciences Group has scored $200m in a series A and crossover round co-led by Novo Holdings and Vivo Capital. Funds will be used to expand the company's presence ...
Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.
Novo Holdings includes subsidiaries Seeds, Venture, Growth and Principal Investments. The headquarters is located in Copenhagen (Denmark) with offices in San Francisco, Boston and Singapore. The total ...
As part of the transaction TA, Biocomposites' majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites' management. The transaction ...
In December 2024, Novo Nordisk announced that the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings was completed.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback